Wanbury Limited
Regd. Office: BSEL Tech Park,
B-Wing, 10th Floor, Sector-30A,
Opp. Vashi Railway Station,
Vashi, Navi Mumbai 400703
Maharashtra, INDIA
Tel: +91-22-6794 2222
+91-22-7196 3222
CIN: L51900MH1988PLC048455
Email: info@wanbury.com
Website: www.wanbury.com

November 6, 2026

To BSE Limited PJ. Towers, Dalal Street Mumbai-400 001. **Script Code:** 524212	To National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. **Script Code:** WANBURY

Sub.: Press release on Standalone and Consolidated Un-audited Financial Results for the second quarter & half year ended 30th September, 2026

As per Regulation 30 of LODR, please find attached herewith copy of press release on Standalone and Consolidated Un-audited Financial Results (UFR) for the second quarter and half year ended 30th September, 2026.

This is for your information and record.

Thanking you.

Yours faithfully,
For Wanbury Limited

JITENDRA JAYANTILAL GANDHI
Digitally signed by JITENDRA JAYANTILAL GANDHI
Date: 2026.11.06 13:20:52 +05'30'

Jitendra J. Gandhi
Company Secretary

Encl.: a/a.

PRESS RELEASE

6th November, 2026, Mumbai: Wanbury Limited, a pharmaceutical company with a presence in the global API market and domestic branded formulations, has announced its financial results for the second quarter and half year ended 30th September 2026.

Financial Highlights

Particulars (Rs. Cr)	Q2 FY27	Q2 FY26	Y-o-Y	Q1 FY27	Q-o-Q
Revenue from Operations	**182.9**	160.1	14.3%	165.6	10.5%
Other Income	**0.1**	0.2	-	0.4	-
EBITDA*	**26.2**	26.0	0.9%	16.6	57.9%
EBITDA Margin (%)	***14.3%***	*16.2%*	*(190) bps*	*10.0%*	*431 bps*
PAT	**11.9**	15.2	(21.7%)	3.2	266.4%
PAT Margin (%)	***6.5%***	*9.5%*	*(299) bps*	*2.0%*	*454 bps*

**Includes Other Income*

Particulars (Rs. Cr)	H1 FY27	H1 FY26	Y-o-Y
Revenue from Operations	**348.5**	323.2	7.8%
Other Income	**0.5**	0.6	-
EBITDA*	**42.8**	50.8	(15.7%)
EBITDA Margin (%)	***12.3%***	*15.7%*	*(342) bps*
PAT	**15.1**	28.7	(47.2%)
PAT Margin (%)	***4.3%***	*8.9%*	*(453) bps*

**Includes Other Income*

For the quarter ended September 30, 2026

- Revenue from Operations stood at Rs. 182.9 crore, compared to Rs. 160.1 crore in Q2 FY26, registering a growth of 14.3% YoY, and Rs. 165.6 crore in Q1 FY27, a growth of 10.5% QoQ. The quarter marked a recovery in Revenue and Profitability from the disruption caused by the crisis in West Asia in Q1 FY27.
- Gross profit stood at Rs. 99.1 crore, compared to Rs. 93.2 crore in Q2 FY26 and Rs. 86.9 crore in Q1 FY27. Gross margin improved to 54.2% from 52.5% in Q1 FY27, as a substantial part of the increase in input costs was passed on to customers during the quarter. Gross margin remained below the 58.2% recorded in Q2 FY26, as prices of solvents and other crude oil

linked raw materials continued to remain elevated in the aftermath of the West Asia crisis. The balance of the cost increase is expected to be passed on in the coming quarter.

- EBITDA (including other income) stood at Rs. 26.2 crore, compared to Rs. 26.0 crore in Q2 FY26 and Rs. 16.6 crore in Q1 FY27, registering a growth of 57.9% QoQ. EBITDA margin improved to 14.3% from 10.0% in Q1 FY27, against 16.2% in Q2 FY26.
- Finance costs reduced to Rs. 6.3 crore, from Rs. 8.0 crore in Q1 FY27 and Rs. 7.1 crore in Q2 FY26, reflecting the refinancing of borrowings at a lower interest rate effective 1st July 2026.
- Profit before tax stood at Rs. 15.7 crore, compared to Rs. 15.2 crore in Q2 FY26 and Rs. 4.6 crore in Q1 FY27, registering a growth of 3.7% YoY.
- PAT stood at Rs. 11.9 crore, compared to Rs. 15.2 crore in Q2 FY26 and Rs. 3.2 crore in Q1 FY27, with EPS of Rs. 3.40 as against Rs. 4.58 in Q2 FY26 and Rs. 0.93 in Q1 FY27. The YoY decline in PAT is on account of provision for deferred tax liabilities created, beginning FY27.
- For H1 FY27, Revenue from Operations stood at Rs. 348.5 crore, a growth of 7.8% over H1 FY26, with EBITDA of Rs. 42.8 crore and PAT of Rs. 15.1 crore. Net cash generated from operating activities stood at Rs. 37.5 crore in H1 FY27, against net cash used of Rs. 5.7 crore in H1 FY26.
- The Company has presented consolidated financial results for this quarter, following the incorporation of Wanbury Skin Health Limited, an 82% subsidiary, during the quarter. On a consolidated basis, Revenue from Operations stood at Rs. 182.9 crore, EBITDA at Rs. 22.9 crore and PAT at Rs. 8.5 crore for Q2 FY27, after absorbing a loss of Rs. 3.4 crore in the subsidiary on expenses incurred ahead of its commercial launch in October 2026.

Business Highlights

- The Company will resume dispatches of Ketamine HCl (anaesthetic) API in the current quarter, following the completion of various subject matter expert regulatory audits, with the first dispatches planned in November 2026 itself.
- The Company is expanding its API portfolio by validating new products, including Quetiapine Fumarate, Sitagliptin and Empagliflozin, with regulatory filings planned in the coming quarters. These APIs are expected to be available for sale in semi-regulated markets in the interim period.
- During July and August 2026, the Company **received nine "No DMF Deficiency" letters from the USFDA for its Metformin HCl Drug Master File**, issued as part of the USFDA's review of ANDAs filed by the Company's customers. In the same period, the Company also received "No DMF Deficiency" letters for Paroxetine HCl and Diphenhydramine HCl, opening up new business opportunities with customers in the regulated US market.
- The Company received approval from the European Directorate for the Quality of Medicines and Healthcare (EDQM) for its new product, **Rivaroxaban API, in the form of a Certificate of Suitability (CEP)**. This will enable the Company to meet customer demand in the EU and other markets accepting CEP.
- The Company's API manufacturing site at Tanuku, Andhra Pradesh **received the GMP Compliance Certificate from Australia's Therapeutic Goods Administration (TGA)** on 28th October 2026, following an inspection conducted on 8th and 9th June 2026. The certificate

covers six APIs: Metformin HCl, Tramadol HCl, Sertraline HCl, Diphenhydramine HCl, Mefenamic Acid and Paroxetine HCl Hemihydrate, and is valid until 9th December 2028. The TGA will now proceed with issuing GMP clearances to Australian sponsors, enabling supply of the approved APIs to the Australian market.

- The Company commercialised a new Metformin DC (directly compressible) business in Saudi Arabia, with an annual revenue potential of about Rs. 10 crore. In Mexico, the Company's customer won a two-year tender for the supply of Metformin, valued at approximately Rs. 15 crore per annum.
- The new manufacturing block at the Andhra Pradesh site remains under validation for new APIs. The Company expects progress on new product launches towards the end of the current financial year, which will reflect in performance in the coming year, and continues to strengthen the pipeline of products under evaluation for commercialisation.
- The Patalganga facility received the "Certificate of Excellence" from the National Safety Council for safety performance for the third consecutive year, and the Tanuku facility received the "Best Employer Award" from the Government of Andhra Pradesh in recognition of its employee practices and workplace culture.
- Wanbury Skin Health Limited, a subsidiary incorporated during the quarter, **launched its berrysoft™ baby product range across multiple states in India** in October 2026, marking the Company's entry into the paediatric dermatology segment. The range comprises Gentle Bathing Bar, Gentle Body Wash, Foam Shampoo and Syndet Handwash, with Moisturising Lotion, Diaper Rash Cream and Moisturising Cream in the pipeline. The subsidiary has received GST registration in five states and CFA drug licences in Mumbai, Jaipur, Patna and Ambala, and will leverage the Company's existing relationships with paediatricians, where it already markets its cough and cold products.

Commenting on the performance, Mr. Mohan Rayana, Director of Wanbury Limited, said,

"Q2 FY27 marks a recovery from the disruption caused by the West Asia crisis in the previous quarter. Revenue from Operations grew 10.5% sequentially and 14.3% year on year, EBITDA margin improved to 14.3% from 10.0% in Q1 FY27, and PAT rose to Rs. 11.9 crore from Rs. 3.2 crore.

Prices of solvents and other crude oil linked raw materials remained elevated through the quarter in the aftermath of the crisis. We have passed on a substantial part of this increase to our customers during the quarter, which is reflected in the sequential improvement in gross margin, and the balance will be passed on in the coming quarter. Margins and profitability on a year-on-year basis still carry the lingering effect of higher input costs, and we expect them to recover fully as the pass-through completes.

Finance costs have reduced following the refinancing of our borrowings at a lower interest rate, and this benefit will continue in the coming quarters.

On the operational front, we received nine 'No DMF Deficiency' letters from the USFDA for Metformin HCl along with similar letters for Paroxetine HCl and Diphenhydramine HCl, a CEP for Rivaroxaban API from EDQM, and the TGA GMP compliance certificate for our Tanuku site. We added new Metformin business in Saudi Arabia and Mexico, and launched our berrysoft™ baby range through Wanbury Skin Health Limited, marking our entry into paediatric dermatology.

On new API product launches, we expect progress towards the end of the current financial year, which will reflect in our performance in the coming year. We continue to work actively on product commercialisation by strengthening the pipeline of products under evaluation.

We expect a better performance on both the topline and profitability fronts in the second half of the year, driven by complete recovery of margins within the existing portfolio and commercialisation of newer products."

About Wanbury Ltd:

Established in 1988, listed on the National Stock Exchange of India Ltd (Code: WANBURY) and BSE Ltd (Code: 524212). The company has a strong presence in the API global market and domestic branded formulations, with its APIs being exported to over 50 countries and a pan-India formulations presence. The company has USFDA and EUGMP approved facilities at Tanuku (Andhra Pradesh) and Patalganga (Maharashtra).

The API product portfolio includes antidiabetic, antidepressant, pain management, antihistamine and anti-inflammatory products, with various other products in the pipeline. The company's clients include some of the leading global generic players.

In formulations, the company has a wide presence across major therapeutic categories like cough and cold solutions, gynaecology, orthopaedics, nutraceuticals, gastrointestinal, anti-inflammatory and analgesics.

For more details on Wanbury Ltd.: https://www.wanbury.com/

For any Investor Relations query, please contact:

Jitendra J. Gandhi **Company Secretary,** **Wanbury Limited** jitendra.gandhi@wanbury.com	**Smit Shah / Hanishi Shah** **PR Agency, Adfactors PR** smit.shah@adfactorspr.com hanishi.shah@adfactorspr.com	**Sayam Pokharna** **IR Advisor, TIL Advisors Private Limited** sayam@theinvestmentlab.in

Forward- Looking Statements:

This document may contain statements, which reflect management's current views and estimates and could be construed as forward-looking statements. The future involves certain risks and uncertainties and could cause actual results to differ materially from the current views being expressed. Potential risks and uncertainties include factors such as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.